Theriva Biologics, Inc. filings document a Nevada clinical-stage biotechnology issuer with common stock listed on the NYSE American under TOVX. The company’s Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical and regulatory updates for VCN-01, and material-event disclosures tied to its oncology development programs.
Theriva Biologics proxy statements cover stockholder meeting mechanics, governance matters and shareholder approval proposals related to warrant exercises and potential common-stock issuance under NYSE American rules. Other 8-K disclosures record material definitive agreements, including the SYN-020 license arrangement, alongside capital-structure, voting and corporate-update information relevant to the company’s development-stage business.
Theriva Biologics, Inc. (TOVX) stockholders approved a charter amendment permitting the Board, at its discretion, to increase authorized common stock to 500,000,000 shares. The Board may decide not to file the amendment, so the increase is not automatic.
Stockholders also approved issuance of up to 16,184,560 common shares upon exercise of warrants issued in a private placement that closed October 17, 2025, ratifying the prior annual-meeting approval. At the special meeting, 16,754,223 shares were present or represented by proxy, out of 45,892,688 shares outstanding as of October 9, 2026. The approved adjournment proposal was not used because Proposals 1 and 2 received sufficient votes at the meeting as convened.
Theriva Biologics, Inc. reported a $6.732 million net loss for the nine months ended September 30, 2026, compared with $21.743 million in the same 2025 period. It used $8.401 million in operating cash and had $8.473 million in cash and cash equivalents at September 30. The company sold 10,204,319 shares through its at-the-market agreement for $2.303 million in net proceeds.
Management believes cash on hand will fund its current plans into the first quarter of 2027, including recruitment in the VIRAGE2 study, but said additional funding will be needed for long-term follow-up and future trials. The company disclosed substantial doubt about its ability to continue as a going concern. Under a license agreement, Rasayana Therapeutics received worldwide rights to SYN-020; Theriva received $300,000 upfront and is eligible for development and sales milestones of up to $16 million and $22 million, respectively, plus royalties.
In a subsequent event, Theriva reported that Biossil Labs acquired rights to its SYN-004, SYN-007 and SYN-006 portfolio. Theriva received $350,000 upfront and is eligible for regulatory and sales-related milestone payments and royalties.
Theriva Biologics, Inc. reported a net loss attributable to common stockholders of $1.471 million for the quarter ended September 30, 2026, compared with $4.361 million a year earlier. Nine-month license revenue was $300,000. General and administrative expense decreased 51% to $923,000, and research and development expense decreased 76% to $612,000. Cash and cash equivalents were $8.473 million as of September 30, 2026, with cash runway into Q1 2027.
In October 2026, Theriva completed the sale of SYN-004 (ribaxamase) and its related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. for $350,000 upfront, up to $91 million in aggregate milestones, and royalties. Detailed analyses of the VIRAGE Phase 2b trial data were published in Nature Medicine.
For VIRAGE2, a Phase 2a study of more frequent, longer-duration VCN-01 dosing in metastatic pancreatic ductal adenocarcinoma, enrollment is expected to complete in Q4 2026; initial pharmacodynamic and safety/tolerability data are expected by Q3 2027. The trial is expected to enroll 6 evaluable patients.
Theriva Biologics, Inc. (TOVX) completed the sale to Biossil Labs Inc. on October 30, 2026, of assets relating to SYN-004, including SYN-007, and certain assets related to SYN-006. Biossil assumed specified post-closing liabilities; Theriva retained other liabilities. Biossil controls development and commercialization and agreed to use commercially reasonable efforts to develop and obtain regulatory approval for at least one product.
Theriva received $350,000 at closing and is eligible for up to $3 million in regulatory milestones, up to $88 million in sales milestones upon achievement of specified cumulative worldwide net sales thresholds, and low single-digit royalties on net product sales subject to a $250 million cap.
Theriva paid PREV ABR LLC $140,000 at closing. It must pay PREV specified shares of milestone, royalty and other consideration received, subject to an aggregate $13.0 million cap that includes the closing payment. Enrollment in the SYN-004 Phase 1b/2a trial is paused after two of three cohorts were completed; Theriva identifies VCN-01 as its lead product candidate.
Theriva Biologics, Inc. is asking stockholders to approve raising authorized common stock to 500,000,000 shares, with the amendment to be filed only if stockholders approve and the Board still deems it advisable. The charter currently authorizes 350,000,000 common shares; a previously approved increase to 450,000,000 has not been filed. The Board may file the proposed amendment within one year after stockholder approval.
Stockholders are also asked to ratify and confirm, and if needed newly approve, issuance of up to 16,184,560 common shares upon exercise of warrants issued in a 2025 private placement. The warrants have an initial exercise price of $0.54 per share; full cash exercise could yield up to approximately $8.7 million in gross proceeds. They become exercisable on or after the effective date of stockholder approval, and exercise would dilute existing holders.
The third proposal would permit adjournment if needed to solicit additional votes. The special meeting is scheduled for November 18, 2026, with October 9, 2026 as the record date. The Board recommends voting for all three proposals.
Theriva Biologics, Inc. asks stockholders to approve increasing authorized common stock to 500,000,000 shares, effective only after stockholder approval and if the Board still deems filing the amendment advisable. The charter currently authorizes 350,000,000 shares; stockholders approved 450,000,000 at the August 3, 2026 annual meeting, but that amendment has not been filed.
Stockholders are also asked to ratify the prior approval and, to the extent necessary, approve issuance of up to 16,184,560 shares upon exercise of warrants issued to institutional investors in the October 17, 2025 private placement. The warrants have an initial $0.54 exercise price, and all exercised for cash could generate up to approximately $8.7 million in gross proceeds. Exercise is available on or after stockholder approval; a full exercise would reduce existing holders’ ownership interests. A third proposal would permit adjournment to solicit additional votes if needed. The Board recommends FOR all three proposals.
Theriva Biologics, Inc. reports that it remains a clinical-stage oncology company focused on its oncolytic adenovirus platform, led by VCN‑01 for pancreatic cancer and retinoblastoma. For the six months ended June 30, 2026, it recorded $300,000 of license revenue from a new out‑license of SYN‑020 and a net loss of $5.3 million, narrower than the prior‑year period.
Cash and cash equivalents totaled $11.3 million, with total assets of $34.9 million and stockholders’ equity of $12.2 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital or strategic transactions. A 2025 restructuring that reduced headcount by 32% is expected to save about $1.8 million annually and, together with other cuts, extend the cash runway into the first quarter of 2027, though current resources only fully cover certain limited trials and obligations.
During the period Theriva entered a license agreement with Rasayana Therapeutics that provided the $300,000 upfront payment and potential future milestones and royalties, continued to benefit from Spanish R&D tax credits, and modestly reduced its contingent consideration liability linked to the VCN acquisition to $9.8 million.
Theriva Biologics, Inc. reported second-quarter 2026 results and a clinical update. The company dosed the first patients in the VIRAGE2 Phase 2a study of VCN-01 in metastatic pancreatic ductal adenocarcinoma, evaluating more frequent repeated dosing to refine a regimen for potential future Phase 3 evaluation.
For the quarter ended June 30, 2026, general and administrative expenses were $2.0 million, down from $11.2 million a year earlier, largely due to a prior-year $9.2 million increase in the fair value of contingent consideration; R&D expenses declined to $1.3 million from $2.0 million. Net loss attributable to common stockholders was $3.2 million, or $0.07 per share, versus $13.1 million, or $1.93 per share, in the prior-year quarter.
Cash and cash equivalents totaled $11.3 million as of June 30, 2026, compared with $13.1 million at December 31, 2025, and the company states this provides a cash runway into the first quarter of 2027. An exploratory trial of SYN-004 remains open but enrollment is paused pending grant, partnership or other funding.
Theriva Biologics announced dosing of the first patient in VIRAGE2, a Phase 2a, proof-of-concept trial testing more frequent repeated dosing of its oncolytic adenovirus VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma patients receiving standard gemcitabine/nab-paclitaxel chemotherapy. The single-arm, open-label study will enroll 6 evaluable patients at a site in Spain, each planned to receive at least three VCN-01 “macrocycles” about two months apart. Primary objectives focus on safety and VCN-01 viral genome levels in blood, with secondary endpoints including response rates and survival.
Enrollment is expected to complete in H2 2026, with initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027. VIRAGE2 builds on the earlier VIRAGE Phase 2b study in metastatic pancreatic cancer, where patients given two VCN-01 doses plus chemotherapy exhibited improved overall survival, progression-free survival, and duration of response versus chemotherapy alone, and on EMA and FDA feedback supporting exploration of more frequent dosing to guide a potential future pivotal Phase 3 trial.
Theriva Biologics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on August 3, 2026. Stockholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the maximum shares of common stock issuable under the plan from 4,500,000 to 6,500,000.
Four directors were elected to serve until the next annual meeting, and BDO USA, P.C. was ratified as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Stockholders also approved an amendment to increase the number of authorized shares of common stock, the issuance of common stock upon exercise of outstanding warrants, and a proposal permitting adjournment of the meeting, although adjournment was ultimately not needed.